Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Fig. 1

Mid-size NGS gene panels vs conventional molecular diagnostics. These new companion assays introduce two major conceptual changes: (a) routine molecular diagnosis no longer focuses on single genes, but encompasses a comprehensive set of alterations, inspiring (b) multidisciplinary cancer treatment at outset, and progressively narrowing down indications for single-marker companion diagnostics

Back to article page